Plain-English translation of NCT03678025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two approaches for men with advanced prostate cancer that has spread to other parts of the body. All participants receive standard hormone therapy to shrink the cancer. The question being tested is whether adding surgery to remove the prostate or radiation therapy to the prostate — in addition to the hormone treatment — helps patients live longer and have better quality of life.
Doctors know that hormone therapy helps control advanced prostate cancer, but they don't yet know whether treating the original prostate tumor with surgery or radiation gives patients an additional benefit. This trial will answer that important question.
You likely qualify if…
You likely don't qualify if…
All participants start with standard hormone therapy (delivered either as injections, implants, or surgery to lower testosterone). After 5–7 months, participants are randomly assigned to continue hormone therapy alone, or to also receive either surgery to remove the prostate or radiation therapy to the prostate. Participants will have regular clinic visits, blood tests, and imaging scans to monitor how they're doing. The study also asks participants to complete questionnaires about urinary function, pain, and quality of life at several time points over 3 years.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States